Press Releases
Nuvera PURE Reports name 2022 “best-in-class” pharmaceutical companies in oncology, neurology and immunology
Nuvera Life Science Consulting, part of Ashfield Engage, is pleased to announce its second annual awards for the three pharmaceutical companies designated as “best-in-class”...
Drug Research
EC Authorizes Opdualag From BMS As A Melanoma Treatment
The fixed-dose combination Opdualag (nivolumab and relatlimab) from Bristol Myers Squibb (BMS) has received clearance from the European Commission for use as the first-line...
News
GAVI Funds To Enable Quick Finances For The Next Pandemic
According to Chief Executive Seth Berkley of the global vaccination alliance GAVI, the organisation has set up financial structures that would enable it to...
Drug Research
Bluebird Hits $3m Mark With Gene Therapy After FDA Approval
Within one firm, the title of most costly treatment in the world has changed hands within a month.
Bluebird Bio has received an FDA fast...
Drug Research
First Next-Gen Parkinsons Med To Be Made By Neuron23, QIAGEN
QIAGEN and Neuron23TM Inc., an early-stage biotechnology company focused on creating precision medications for genetically defined neurological and immunological illnesses, have announced a partnership...
Drug Research
Australia Permits New Treatment For Rare Bile Duct Cancer
Australia has authorised the use of a new targeted therapy for the treatment of cholangiocarcinoma, a rare bile duct cancer. The Therapeutic Goods Administration...
Drug Research
Beyfortus From Sanofi And Astrazeneca Is Supported By RSV
Beyfortus has received approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency to treat lower respiratory tract...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read